The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...

CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 22, 2026, Health Canada has approved Gazyva® (obinutuzumab) for ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treated with calcineurin inhibitors vs ...

This transcript has been edited for clarity. Matthew A. Sparks, MD: I'm Dr Matthew Sparks, and welcome to Medscape's InDiscussion podcast series on chronic kidney disease. Today we'll be discussing ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

Lupus nephritis is a serious complication of lupus that is caused by inflammation of the kidneys. It affects up to 60% of people with lupus and usually occurs within 5 years of diagnosis. If left ...

IN patients with systemic lupus erythematosus, renal involvement is considered a poor prognostic sign. 1–5 Pollak et al. 1 reported mean survival times of fourteen months for patients with lupus ...

Patients with severe lupus nephritis who have both diffuse proliferative (class IV) and membranous (class V) lesions on biopsy can be refractory to current monotherapy treatments. Bao et al. compared ...

New biomarkers for Lupus Nephritis are the presence of clotting factors in urine, both those proteins that promote clots and those that deplete them. Urine protein biomarkers for lupus nephritis are ...